It’s not just Tim Boreham recommending POH.
This week, James Dunn (in the Switzer Report) has also recommended POH as one of “Four Promising Biotechs for 2018”.
Dunn’s recommendation doesn’t even take into account the Mylan arbitration outcome – that’s not even mentioned.
What is specifically mentioned are diclo gel, Vital ET, the Terumo oxymorphone patch deal and skincare products.
Buy Recommendation The Australian, page-31
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 34 | 46009211 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 46070683 | 28 |
View Market Depth
| Last trade - 11.05am 30/09/2024 (20 minute delay) ? |
| AVE (ASX) Chart |
Day chart unavailable